Treatable traits: Toward precision medicine of chronic airway diseases

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 410-419

  Agusti, Alvar ^a   Bel, Elisabeth ^b   Thomas, Mike ^c   Vogelmeier, Claus ^d   Brusselle, Guy ^e,f   Holgate, Stephen ^g   Humbert, Marc ^h   Jones, Paul ⁱ   Gibson, Peter G ^j   Vestbo, Jørgen ^k   Beasley, Richard ^l   Pavord, Ian D ^m  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^m UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONTROL STRATEGY; DISEASE CONTROL; HUMAN; PATIENT ASSESSMENT; PATIENT CARE; PATIENT CARE PLANNING; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; HUMANS; INFLAMMATION; PHENOTYPE; PRECISION MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84958073595     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01359-2015     Document Type: Review

References (76)

1. Vanfleteren LEGW, Kocks JWH, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 2014; 69: 72-79.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795.
3. Jameson JL, Longo DL. Precision medicine - personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-2234.
4. Agusti A, Anto JM, Auffray C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Am J Respir Crit Care Med 2015; 191: 391-401.
5. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011; 183: 1129-1137.
6. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
7. Diez D, Agusti A, Wheelock CE. Network analysis in the investigation of chronic respiratory diseases: from basics to application. Am J Respir Crit Care Med 2014; 190: 981-988.
8. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46: 622-639.
9. Vestbo J, Hurd SS, Agusti A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187: 347-365.
10. Global Strategy for Asthma Management and Prevention. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. Asthma, COPD and asthma-COPD overlap syndrome (ACOS). 2014. http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf Date last accessed: December 1, 2015.
11. Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385: 1789-1798.
12. Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma-COPD overlap syndrome: a staging post to a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719-728.
13. Snyder LJ. Eye of the beholder: Johannes Vermeer, Antoni van Leeuwenhoek, and the reinvention of seeing. 1 Edn. New York, Norton, 2015.
14. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
15. Orie NG, Sluiter HJ, De Vries K, et al. The host factor in bronchitis. In: Orie NG, Sluiter HJ, eds. Bronchitis. Assen, Royal Vangorcumd, 1961; pp. 43-59.
16. Orie NG, Slutter HJ, De Vries K, et al. [Chronic nonspecific respiratory diseases]. Ned Tijdschr Geneeskd 1961; 105: 2136-2139.
17. Agusti A. The path to personalized medicine in COPD. Thorax 2014; 69: 857-864.
18. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68: 687-690.
19. Martinez FD, Vercelli D. Asthma. Lancet 2013; 382: 1360-1372.
20. Demoly P, Gueron B, Annunziata K, et al. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010; 19: 150-157.
21. Turner S, Thomas M, von Zeigenweidt J, et al. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009; 94: 16-22.
22. Pavord ID, Shaw DE, Gibson PG, et al. Inflammometry to assess airway diseases. Lancet 2008; 372: 1017-1019.
23. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172: 453-459.
24. Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132: 821-827.
25. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983-990.
26. Honkoop PJ, Loijmans RJ, Termeer EH, et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol 2015; 135: 682-688.
27. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-811.
28. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: e27.
29. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73-78.
30. Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014; 11: 1011-1017.
31. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2: 891-901.
32. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086-1096.
33. Bush A, Kleinert S, Pavord ID. The asthmas in 2015 and beyond: a Lancet Commission. Lancet 2015; 385: 1273-1275.
34. Barnes PJ, Bonini S, Seeger W, et al. Barriers to new drug development in respiratory disease. Eur Respir J 2015; 45: 1197-1207.
35. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
36. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
37. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
38. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
39. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007; 3: 124.
40. Vermeire PA, Pride NB. A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490-496.
41. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
42. Ritchie MD, de Andrade M, Kuivaniemi H. The foundation of precision medicine: integration of electronic health records with genomics through basic, clinical, and translational research. Front Genet 2015; 6: 104.
43. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418-424.
44. 25-75/FVC in families with severe, early onset COPD. Thorax 2004; 59: 396-400.
45. Tai A, Tran H, Roberts M, et al. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014; 69: 805-810.
46. Lange P, Celli B, Agusti A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111-122.
47. Holgate S, Agusti A, Strieter RM, et al. Drug development for airway diseases: looking forward. Nat Rev Drug Discov 2015; 14: 367-368.
48. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-360.
49. Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J 2014; 44: 1132-1148.
50. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, et al. Variability of hospital resources for acute care of COPD patients: the European COPD Audit. Eur Respir J 2014; 43: 754-762.
51. Agusti A, Fabbri LM. Inhaled steroids in COPD: when should they be used? Lancet Respir Med 2014; 2: 869-871.
52. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10: Suppl., S125-S130.
53. Flecther CM, Gilson JG, Hugh-Jones P, et al. Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions. A report of the conclusions of a CIBA guest symposium. Thorax 1959; 14: 286-299.
54. Sluiter HJ, Koeter GH, de Monchy JG, et al. The Dutch hypothesis (chronic non-specific lung disease) revisited. Eur Respir J 1991; 4: 479-489.
55. NO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115-120.
56. Zhang XY, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 2014; 44: 1137-1145.
57. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 1583-1589.
58. Vertigan AE, Theodoros DG, Gibson PG, et al. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax 2006; 61: 1065-1069.
59. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
60. McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68: 691-694.
61. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
62. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376: 803-813.
63. McDonald VM, Simpson JL, Higgins I, et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011; 40: 42-49.
64. McDonald VM, Higgins I, Simpson JL, et al. The importance of clinical management problems in older people with COPD and asthma: do patients and physicians agree? Prim Care Respir J 2011; 20: 389-395.
65. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
66. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
67. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366: 489-490.
68. National Institute for Health and Care Excellence (NICE). Asthma - diagnosis and monitoring. www.nice.org.uk/guidance/indevelopment/gid-cgwave0640 Date last accessed: December 1, 2015.
69. Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219-223.
70. US Food and Drug Administration. Guidances (drugs). http://www.fda.gov/Drugs/GuidanceComplianceRegulatory-Information/Guidances/default.htm Date last accessed: December 1, 2015.
71. Akhmetov I, Ramaswamy R, Akhmetov I, et al. Market access advancements and challenges in "drug-companion diagnostic test" co-development in Europe. J Pers Med 2015; 5: 213-228.
72. Batrla R, Jordan BW. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. Ann N Y Acad Sci 2015; 1346: 71-80.
73. Jorgensen JT. Companion diagnostics: the key to personalized medicine. Foreword. Expert Rev Mol Diagn 2015; 15: 153-156.
74. Caberlotto L, Lauria M. Systems biology meets-omic technologies: novel approaches to biomarker discovery and companion diagnostic development. Expert Rev Mol Diagn 2015; 15: 255-265.
75. Silverman EK, Loscalzo J. Developing new drug treatments in the era of network medicine. Clin Pharmacol Ther 2013; 93: 26-28.
76. Bousquet J, Anto J, Sterk P, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011; 3: 43-55.